Pharmaceutical company GlaxoSmithKline has asked the Canadian government to postpone the distribution of party vaccine virus H1N1. The drug manufacturer explained his decision by saying that the vaccine might be associated with a higher frequency of severe allergic reactions from patients.
About 170,000 doses of that vaccine were delivered to Canada late last month, written by Canadian media.
“GSK has taken those steps as a preventive measure, since the Public Health Agency of Canada reported a larger-than-expected number of cases of anaphylaxis (life-threatening immediate systemic hypersensitivity reaction to the allergen) for vaccination of that supplied part, in comparison with others," said in a statement GlaxoSmithKline.
According to officials of the Canadian Health Ministry, there was observed a severe allergic reaction in each of 20,000 patients. However, as per the standard level, the rate should not exceed one anaphylaxis per 100,000 vaccinations.
According to Canadian media,
allergic reactions were transient and did not lead to any serious consequences. According to CTV News from 6.6 million doses of vaccine in Canada, there have been 36 cases of serious adverse reactions in the first minutes after vaccination.
In addition, there reported one fatal case following the application of GlaxoSmithKline vaccine. However, the doctors still are not sure that the tragic outcome was caused by the immunization.
I got to say.... Your service is absolutely superb! I just received my order in the mail. You have just gotten yourself a steady very impressed satisfied customer. Thank you for your excellent service.
Print page